CA2785273A1 - Early marker of proteinuria in patients treated with an anti-vegf treatment - Google Patents

Early marker of proteinuria in patients treated with an anti-vegf treatment Download PDF

Info

Publication number
CA2785273A1
CA2785273A1 CA2785273A CA2785273A CA2785273A1 CA 2785273 A1 CA2785273 A1 CA 2785273A1 CA 2785273 A CA2785273 A CA 2785273A CA 2785273 A CA2785273 A CA 2785273A CA 2785273 A1 CA2785273 A1 CA 2785273A1
Authority
CA
Canada
Prior art keywords
human
podocytes
therapy
proteinuria
urinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2785273A
Other languages
English (en)
French (fr)
Inventor
Vesna D. Garovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Publication of CA2785273A1 publication Critical patent/CA2785273A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2785273A 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-vegf treatment Abandoned CA2785273A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28851409P 2009-12-21 2009-12-21
US61/288,514 2009-12-21
PCT/US2010/061543 WO2011084791A2 (en) 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-vegf treatment

Publications (1)

Publication Number Publication Date
CA2785273A1 true CA2785273A1 (en) 2011-07-14

Family

ID=44306097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2785273A Abandoned CA2785273A1 (en) 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-vegf treatment

Country Status (8)

Country Link
US (4) US20130034861A1 (enExample)
EP (1) EP2517014B1 (enExample)
JP (1) JP5753541B2 (enExample)
AU (1) AU2010339723B2 (enExample)
BR (1) BR112012017767A2 (enExample)
CA (1) CA2785273A1 (enExample)
ES (1) ES2530866T3 (enExample)
WO (1) WO2011084791A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
BR112012017767A2 (pt) 2009-12-21 2019-09-24 Mayo Found Medical Education & Res marcador precoce de proteinúria em pacientes tratados com um tratamento anti-vegf
JP6310861B2 (ja) * 2012-12-26 2018-04-11 原　正則 尿中ポドサイトの検出方法
US11028448B2 (en) 2019-09-20 2021-06-08 The University Of North Carolina At Chapel Hill Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306053D0 (en) 1993-03-24 1993-05-12 Nycomed Pharma As Method and assay
EP1336845B1 (en) 2000-10-27 2013-03-27 DENKA SEIKEN Co., Ltd. Method of diagnosing nephropathy
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2003075016A1 (en) 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
US20030198959A1 (en) * 2002-03-28 2003-10-23 Kurnit David M. Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP2007532913A (ja) 2004-04-16 2007-11-15 ユニバーシティー オブ マサチューセッツ 細胞内病原体の検出法および定量化法
AU2005277350A1 (en) * 2004-08-17 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of pre-selecting patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
CA2672560A1 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universitaet Heidelberg Methods for treating podocyte-related disorders
KR20150041157A (ko) 2007-05-21 2015-04-15 웨이크 포리스트 유니버시티 헬스 사이언시즈 소변으로부터의 전구 세포 및 이를 사용하는 방법
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US20090068683A1 (en) 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
WO2009053987A1 (en) * 2007-10-25 2009-04-30 University Of Bristol Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf)
WO2010065968A1 (en) 2008-12-05 2010-06-10 Myriad Genetics, Inc. Cancer detection markers
WO2010143423A1 (ja) 2009-06-10 2010-12-16 国立大学法人 新潟大学 糖尿病性腎症の検査方法
BR112012017767A2 (pt) 2009-12-21 2019-09-24 Mayo Found Medical Education & Res marcador precoce de proteinúria em pacientes tratados com um tratamento anti-vegf
NZ603482A (en) 2010-05-12 2014-11-28 Tengion Inc Bioactive renal cells
EP2856164B1 (en) 2012-06-01 2018-07-11 Mayo Foundation For Medical Education And Research High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia
EP2904118B1 (en) 2012-10-05 2019-03-20 Hitachi Chemical Co., Ltd. Urine exosome mrnas and methods of using same to detect diabetic nephropathy
WO2015080838A1 (en) 2013-11-27 2015-06-04 Mayo Foundation For Medical Education And Research Detecting podocyte injury in diabetic nephropathy and glomerulonephritis

Also Published As

Publication number Publication date
US10336822B2 (en) 2019-07-02
EP2517014B1 (en) 2014-11-19
US20130034861A1 (en) 2013-02-07
AU2010339723A1 (en) 2012-08-09
US9765137B2 (en) 2017-09-19
US20160060333A1 (en) 2016-03-03
JP2013515268A (ja) 2013-05-02
EP2517014A2 (en) 2012-10-31
AU2010339723B2 (en) 2014-11-06
US20130296397A1 (en) 2013-11-07
US20180002416A1 (en) 2018-01-04
BR112012017767A2 (pt) 2019-09-24
US9213038B2 (en) 2015-12-15
JP5753541B2 (ja) 2015-07-22
ES2530866T3 (es) 2015-03-06
EP2517014A4 (en) 2013-07-17
WO2011084791A2 (en) 2011-07-14
WO2011084791A3 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
Vermeire et al. How, when, and for whom should we perform therapeutic drug monitoring?
Suwannalai et al. Avidity maturation of anti–citrullinated protein antibodies in rheumatoid arthritis
Van Schouwenburg et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients
Stuht et al. Lymphatic neoangiogenesis in human renal allografts: results from sequential protocol biopsies
EP3635407B1 (en) Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
Nurbhai et al. Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients
US10336822B2 (en) Early marker of proteinuria in patients treated with an anti-VEGF treatment
AU2018272054A1 (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
Bertin et al. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: a comparison of three commercially available ELISA kits
US20100015643A1 (en) Method of quantitative determination of antigen protein and quantitative determination kit therefor
Dupont et al. Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?
Jilani et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay
Nguyen et al. Relationship between serum ustekinumab trough concentration and clinical and biochemical disease activity: a real-world study in adult patients with Crohn’s disease
Helmers et al. Sera from anti–Jo‐1–positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells
Sznol et al. Key issues in the management of gastrointestinal immune-related adverse events associated with ipilimumab administration
Rosas et al. Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis
Scott et al. Advances in therapeutic drug monitoring of biologic therapies in inflammatory bowel disease: 2015 in review
CA2859221C (en) Lamin a/c and prelamins as indicators of frailty and vulnerability or resiliency to adverse health outcomes
Fichtner et al. Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study
Caicedo et al. Establishing clinically meaningful ranges of metal hypersensitivity in orthopaedic patients using COVID-19 vaccine-induced adaptive immune responses from fully vaccinated adults
Gill et al. Inflammatory Bowel Disease: Diagnosis and Management
Szántó Crucial Steps for Treatment Optimization and Decision Making in Inflammatory Bowel Disease Management
Kenanidis et al. The serum levels of Receptor Activator of Nuclear Factor-κB Ligand, bone-specific alkaline phosphatase, osteocalcin and osteoprotegerin do not correlate with the radiographically assessed severity of idiopathic hip and knee osteoarthritis
Mendolaro et al. Standard therapeutic approach and new therapies
Muñoz-Villafranca et al. Infliximab and Adalimumab Monitoring versus Clinical Control during Maintenance Therapy in Randomized Patients with Inflammatory Bowel Disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151001

FZDE Discontinued

Effective date: 20181221